BFSG LLC’s Xeris Biopharma Holdings XERS Stock Holding History

BFSG LLC’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,000	Closed	-$6.78K	–	714
2024 Q4	$6.78K	Hold	2,000	–	–	﹤0.01%	538
2024 Q3	$5.7K	Hold	2,000	–	–	﹤0.01%	536
2024 Q2	$4.5K	Hold	2,000	–	–	﹤0.01%	526
2024 Q1	$4.42K	Hold	2,000	–	–	﹤0.01%	552
2023 Q4	$4.7K	Buy	+2,000	New	+$3.69K	﹤0.01%	508

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BFSG LLC's XERS Position: Q1 2025 in Review

BFSG LLC sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 2,000 shares — an estimated $6.78K sold.

BFSG LLC first reported a position in XERS in Q4 2023 and held it in 5 quarters. The position peaked at $6.78K in Q4 2024. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

BFSG LLC reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
BFSG LLC sold 2,000 Xeris Biopharma Holdings shares in Q1 2025, an estimated $6.78K.
BFSG LLC first reported a position in Xeris Biopharma Holdings in Q4 2023 and held it in 5 quarters.
BFSG LLC's Xeris Biopharma Holdings position peaked at $6.78K in Q4 2024.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.